CAS: 95975-55-6; (8R,9S,10R,13S,14S)-17-Ethylidene-10,13-Dimethyl-7,8,9,10,11,12,13,14,15,17-Decahydro-1H-Cyclopenta[a]Phenanthrene-3,16(2H,6H)-Dione

该化合物是一种生物活性类固醇化合物,产自古尔维迪药传统使用的Copiphora mukul树树树脂,因其潜在的药理特性而得到承认,包括抗炎,减脂和抗氧化作用,在结构上被归类为植物酯,gugulsterone,以两种异构形式存在,即E-和Z-gugullsterone(表现出独特的生物活动).研究表明,它可以调节FXR和PXR等核受体,影响胆固醇代谢和乙酸合成,其应用范围扩大到代谢学和内分泌研究,特别是在有关肥胖和甲状腺功能的研究中.Gugulstone因其纯度,稳定性和在实验环境中的可再生性而受到重视.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

  • 3347-58-8 = 95975-55-6
    反应条件:1.1 Reagents: Cyclohexanone Solvents: Toluene; 2 H,Reflux1.2 Reagents: Aluminum Isopropoxide; 0.5 H,105 - 110 °C; 110 °C -> Rt1.3 Reagents: Hydrochloric Acid Solvents: Water; 10 Min,Rt
    标题:Preparation Of Guggulsterone Intermediate
    参考文献:China]

    = 95975-55-6 [标题:Reaction Conditions
    标题:A Process For The Synthesis Of Pharmacologically Active (E/z)-Guggulsterones
    参考文献:India]

    = 95975-55-6 [标题:Reaction Conditions
    标题:Process For Preparing (Z/e)-Guggulsterones From 16-Dehydropregnenolone Acetate
    参考文献:World Intellectual Property Organization]

    = 95975-55-6
    反应条件:1.1 Reagents: N-Hydroxyphthalimide,Oxygen Catalysts: Benzoyl Peroxide,Manganese Oxide (Mno2) Solvents: Cyclohexanone; Rt -> 50 °C; 10 - 15 H,45 - 50 °C
    标题:Green Preparation Of Guggulsterone
    参考文献:China]

    672308-23-5 = 95975-55-6
    反应条件:1.1 Reagents: Aluminum Isopropoxide Solvents: Toluene,Cyclohexanone; Reflux
    标题:Process For Preparing Guggulsterones From 16-Dihydropegnenolone Acetate
    参考文献:World Intellectual Property Organization]

    = 95975-55-6 [标题:Reaction Conditions
    标题:Preparation Method Of Guggulsterone And Intermediate Used Therein
    参考文献:Korea]

    = 95975-55-6 [标题:Reaction Conditions
    标题:A Process For The Preparation Of A Pharmacologically Active Synthetic Z And E Stereoisomeric Mixture Of Guggulsterones
    参考文献:European Patent Organization
5,17(20)-Dien-Pregna-3,16-Diol置于aluminum Isopropoxide,硫酸体系中,用 环己酮,甲苯,环己烷,水 作为反应溶剂,化学反应 4.0H,以50%的收率获得产物香胶甾酮
参考文献:Process For The Synthesis Of Pharmacologically Active (Z/e)-Guggulsterones
标题:Process For The Synthesis Of Pharmacologically Active (Z/e)-Guggulsterones
摘要:该发明涉及一种改进的工艺,用于在三个步骤中生产具有药理活性的合成立体异构混合物古钩甾酮(4).古钩甾酮混合物由z-古钩甾酮[4,17(20)-反-孕二烯-3,16-二酮]和e-古钩甾酮[4,17(20)-顺-孕二烯-3,16-二酮]组成,可以是任何相对比例.该改进工艺包括(a)用过氧化氢对16-去氢孕酮醋酸酯(1)进行环氧化,(b)用肼水合物还原所得环氧化物(2),以及(c)氧化二醇(3).

海关参考信息

专利信息


专利号:US-2005085452-A1
优先权日:2002-09-03
标 题:Process for the synthesis of pharmacologically active (z/e)-guggulsterones
发明人:GOKARAJU GANGA R; GOKARAJU RAMA R; GOTTUMUKKALA VENKATA S; SOMEPALLI VENKATESWARLU
摘要:The invention relates to an improved process for producing pharmacologically active synthetic stereoisomeric mixture of guggulsterones (4) in the three steps. The mixture of gugguisterones consists of Z-guggulsterone [4,17(20)-trans-pregnadiene-3,16-dione] and E-guggulsterone [4,17(20)-cis-pregnadiene-3,16-dione] and could be in any relative ratio. This improved process comprises (a) epoxidation of 16-dehydropregnanolone acetate (1) with hydrogen peroxide (b) reduction of the so obtained epoxide (2) with hydrazine hydrate and (c) oxidation of the diol (3).

专利号:WO-2004021975-A2
优先权日:2002-09-03
标题:An improved process for the synthesis of pharmacologically active (z/e)-guggulsterones

专利号:WO-2004021975-A3
优先权日:2002-09-03
标 题 :An improved process for the synthesis of pharmacologically active (z/e)-guggulsterones
湖南科瑞生物制药股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.kery-pharm.com
企业联系电话:18075956566👤
📞湖南科瑞生物制药股份有限公司 ⚠️参考联系方式
联系人:胡小姐
电话:18075956566
手机:18075956566
传真:0739-3669978

通信地址: 湖南省邵阳市新邵县酿溪镇大坪经济开发区财兴路
邮编:
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖南省邵阳市新邵县酿溪镇大坪经济开发区财兴路
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Shi JJ, Jia XL, Li M, Yang N, Li YP, Zhang X, Gao N, Dang SS. Guggulsterone induces apoptosis of human hepatocellular carcinoma cells through intrinsic mitochondrial pathway. World J Gastroenterol. 2015 Dec 21;21(47):13277-87. doi: 10.3748/wjg.v21.i47.13277.
2: Zhong F, Yang J, Tong ZT, Chen LL, Fan LL, Wang F, Zha XL, Li J. Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression. Oncol Lett. 2015 Sep;10(3):1416-1422. Epub 2015 Jun 19.
3: Shishodia S, Azu N, Rosenzweig JA, Jackson DA. Guggulsterone for Chemoprevention of Cancer. Curr Pharm Des. 2016;22(3):294-306. Review. doi: 10.1007/s12298-014-0271-1. Epub 2014 Nov 22.

合成参考文献


摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
参考文献:10.1074/jbc.m408093200
摘要:Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem. 2004 Nov 05;279(45):47148–58. doi: 10.1074/jbc.m408093200.
参考文献:10.1158/0008-5472.can-07-6696
摘要:Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res. 2008 Jun 01;68(11):4406–15. doi: 10.1158/0008-5472.can-07-6696.
参考文献:10.1002/biof.5520300303
摘要:Yang JY, Della-Fera MA, Rayalam S, Ambati S, Baile CA. Enhanced pro-apoptotic and anti-adipogenic effects of genistein plus guggulsterone in 3T3-L1 adipocytes. Biofactors. 2007;30(3):159–69. doi: 10.1002/biof.5520300303.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知